Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin |
Synonyms | |
Therapy Description |
Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06096844 | Phase III | Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium | Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Recruiting | USA | 0 |
NCT03456076 | Phase III | Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | AUT | AUS | 12 |
NCT02455245 | Phase III | Carboplatin Carboplatin + Vincristine Sulfate | A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma | Unknown status | USA | 0 |
NCT01836029 | Phase II | Cisplatin Cetuximab + Fluorouracil Carboplatin | Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | 0 |
NCT02199171 | Phase I | Carboplatin | Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer | Completed | USA | 0 |
NCT01248962 | Phase II | Carboplatin | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | 3 |
NCT06431633 | Phase II | Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) | Not yet recruiting | ESP | 0 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Active, not recruiting | ITA | GBR | FRA | ESP | BEL | 0 |
NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Completed | 0 | |
NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Completed | USA | POL | ITA | ISR | HUN | GBR | ESP | CZE | CAN | BRA | 2 |
NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin | Avelumab in First-line NSCLC (JAVELIN Lung 100) | Completed | USA | TUR | SVK | ROU | POL | NZL | NLD | LTU | LBN | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CYP | CAN | BRA | BGR | BEL | AUS | 14 |
NCT01493505 | Phase III | Carboplatin Paclitaxel Trebananib | TRINOVA-3 | Terminated | USA | NLD | ITA | GRC | ESP | DNK | DEU | CAN | BEL | AUT | 4 |
NCT03770299 | Phase II | Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) | Withdrawn | 0 | |
NCT01445418 | Phase I | Olaparib Carboplatin | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | Completed | USA | 0 |
NCT03095352 | Phase II | Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | Active, not recruiting | USA | 0 |
NCT02312804 | Phase I | Paclitaxel Carboplatin Infigratinib | Ph Ib/BGJ398/Cervix and Other Solid Tumors | Withdrawn | 0 | |
NCT02341456 | Phase I | Adavosertib Carboplatin Paclitaxel | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | Completed | AUS | 2 |
NCT01459380 | Phase I | Carboplatin Doxorubicin Veliparib Bevacizumab | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT01859741 | Phase Ib/II | Cisplatin Etoposide Carboplatin Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) | Terminated | USA | 0 |
NCT02367794 | Phase III | Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab | A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | SVK | NLD | LVA | LTU | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT02581943 | Phase II | Paclitaxel Pembrolizumab Carboplatin | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | POL | ESP | BEL | AUT | 4 |
NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
NCT04595565 | Phase III | Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) | Active, not recruiting | IRL | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
NCT02032277 | Phase III | Cyclophosphamide + Doxorubicin Veliparib Carboplatin Carboplatin + Paclitaxel | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT02409342 | Phase III | Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin | A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | 7 |
NCT02561832 | Phase I | Cyclophosphamide Olaparib Carboplatin | A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer | Terminated | USA | ESP | 0 |
NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Active, not recruiting | USA | TUR | ROU | POL | NOR | LVA | LTU | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | ARG | 9 |
NCT01358877 | Phase III | Pertuzumab Epirubicin Cyclophosphamide Paclitaxel Docetaxel Trastuzumab Fluorouracil Carboplatin Doxorubicin | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) | Active, not recruiting | USA | SWE | SVN | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | ARG | 17 |
NCT03498521 | Phase II | Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) | Active, not recruiting | TUR | ROU | POL | NOR | NLD | LVA | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | BRA | BGR | AUT | AUS | 8 |
NCT03206203 | Phase II | Atezolizumab + Carboplatin Carboplatin | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02389751 | Phase I | Carboplatin Paclitaxel Ganetespib | A Study of Ganetespib in Combination With Chemoradiation | Completed | USA | 0 |
NCT00993655 | Phase III | Cisplatin Paclitaxel Carboplatin | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | GBR | ESP | CAN | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
NCT01664754 | Phase I | Pemetrexed Disodium Carboplatin Exemestane | Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01927744 | Phase II | Docetaxel + Erlotinib Cisplatin Docetaxel Carboplatin | Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | Recruiting | USA | 0 |
NCT00565851 | Phase III | Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 2 |
NCT00303849 | Phase Ib/II | Filgrastim Etoposide + Melphalan Carboplatin Pegfilgrastim | Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma | Completed | USA | 0 |
NCT01248949 | Phase I | Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | AUS | 0 |
NCT05846789 | Phase II | Carboplatin + Tocilizumab Carboplatin | Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers | Recruiting | USA | 0 |
NCT05583188 | FDA approved | Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium | Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) | Terminated | USA | 0 |
NCT01249443 | Phase I | Carboplatin Vorinostat Paclitaxel | Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | Terminated | USA | 0 |
NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT04486833 | Phase Ib/II | Osimertinib + Quaratusugene Ozeplasmid Carboplatin Cisplatin | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) | Recruiting | USA | 0 |
NCT01820754 | Phase II | Cisplatin Ipilimumab Carboplatin Paclitaxel | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT00828009 | Phase II | Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01526603 | Phase I | Melphalan Etoposide Filgrastim Tretinoin Carboplatin | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | Completed | USA | 0 |
NCT02035345 | FDA approved | Carboplatin | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | Terminated | USA | 0 |
NCT02605915 | Phase I | Atezolizumab + Trastuzumab Docetaxel Carboplatin Pertuzumab | Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer | Completed | USA | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT03903835 | Phase III | Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide | ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) | Recruiting | SWE | NOR | CHE | BEL | 0 |
NCT01493843 | Phase II | Carboplatin Pictilisib Bevacizumab | Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | Completed | USA | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 3 |
NCT01042522 | Phase II | Carboplatin Cisplatin Paclitaxel Etoposide Bleomycin | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | Unknown status | USA | 0 |
NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT06528496 | Phase II | Irinotecan Doxorubicin Ifosfamide Sargramostim Etoposide Temozolomide Carboplatin Naxitamab Vincristine Sulfate Topotecan Cyclophosphamide | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Recruiting | USA | 0 |
NCT01633541 | Phase II | AT-101 Carboplatin Cisplatin Docetaxel | Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer | Completed | USA | 0 |
NCT01357161 | Phase II | Carboplatin Adavosertib Paclitaxel | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Completed | 0 | |
NCT05635708 | Phase II | Nab-paclitaxel Cisplatin BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Recruiting | USA | ROU | ITA | FRA | ESP | CAN | BRA | AUS | 7 |
NCT01505569 | Phase I | Filgrastim Busulfan + Melphalan Etoposide + Ifosfamide Thiotepa Carboplatin | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | Completed | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
NCT04671667 | Phase II | Cisplatin Pembrolizumab Carboplatin | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
NCT03414684 | Phase II | Carboplatin + Nivolumab Carboplatin | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Completed | USA | ESP | CAN | BEL | 0 |
NCT04038502 | Phase II | Olaparib Carboplatin | Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA) | Recruiting | USA | 0 |
NCT04711824 | Phase Ib/II | Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) | Recruiting | USA | 0 |
NCT02122770 | Phase I | Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01218048 | Phase II | Cisplatin Carboplatin Cetuximab | ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03126916 | Phase III | Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Active, not recruiting | USA | CAN | 1 |
NCT02419495 | Phase I | Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin | Selinexor in Combination With Standard Chemotherapy | Terminated | USA | 0 |
NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Completed | 0 | |
NCT05067530 | Phase II | Paclitaxel Palbociclib Carboplatin Carboplatin + Paclitaxel Paclitaxel + Palbociclib | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study (CAREGIVER) | Not yet recruiting | POL | 0 |
NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed | USA | 0 |
NCT05492123 | Phase II | Ipilimumab + Nivolumab Cisplatin Cisplatin + Nivolumab Carboplatin + Nivolumab Carboplatin | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | Recruiting | BRA | 0 |
NCT01281150 | Phase I | Veliparib Paclitaxel Carboplatin | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01898494 | Phase II | Cisplatin Carboplatin | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | Active, not recruiting | USA | 0 |
NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT01450761 | Phase III | Cisplatin Ipilimumab Carboplatin Etoposide | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 13 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT06564844 | Phase III | Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) | Not yet recruiting | USA | TUR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | 6 |
NCT01700400 | Phase I | Carboplatin Everolimus Bevacizumab Pemetrexed Disodium | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | Completed | USA | 0 |
NCT01407562 | Phase I | Carboplatin Paclitaxel Pazopanib | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT01064479 | Phase II | Erlotinib Carboplatin Docetaxel Cisplatin | Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck | Completed | USA | 0 |
NCT00492687 | Phase II | Carboplatin Temozolomide Tamoxifen | Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas | Unknown status | USA | 0 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01928160 | Phase II | Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | Withdrawn | 0 | |
NCT00254319 | Phase II | Carboplatin Bevacizumab + Pemetrexed Disodium | Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | Unknown status | USA | 0 |
NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
NCT04364048 | Phase II | Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT06099769 | Phase II | Capecitabine Paclitaxel Enzalutamide Enzalutamide + Mifepristone Eribulin Carboplatin | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05374512 | Phase III | Eribulin Nab-paclitaxel Paclitaxel Datopotamab deruxtecan Carboplatin Capecitabine | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy | Active, not recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 10 |
NCT01187199 | Phase I | Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | Active, not recruiting | USA | 0 |
NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | POL | NZL | ISR | GBR | ESP | DNK | BRA | AUS | 2 |
NCT01437449 | Phase II | Cetuximab + Cisplatin + Docetaxel Carboplatin | Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Completed | USA | 0 |
NCT02437812 | Phase II | Paclitaxel Carboplatin Metformin | Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma | Unknown status | USA | 0 |
NCT02531932 | Phase II | Carboplatin Everolimus | Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02264990 | Phase III | Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Completed | USA | TUR | NZL | NLD | ISR | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | AUS | ARG | 5 |
NCT01344824 | Phase II | Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium | Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers | Completed | USA | 0 |
NCT04989283 | Phase II | Carboplatin Atezolizumab + Cisplatin Atezolizumab + Paclitaxel Atezolizumab + Etoposide Cisplatin Etoposide Paclitaxel Atezolizumab + Carboplatin | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03631199 | Phase III | Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) | Active, not recruiting | USA | TUR | SWE | SVK | ROU | POL | NOR | NLD | LBN | ITA | ISL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS | ARG | 15 |
NCT02281955 | Phase II | Cisplatin Carboplatin Cetuximab | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC | Active, not recruiting | USA | 0 |